Dr. Clay Siegall, the founder and CEO of Seattle Genetics, has had a significant input as far as research and development of targeted therapy drugs is concerned. Through a published interview with Inspirery, the research guru explained how he started in research and entrepreneurship, as well as what motivated him to venture into research.
Medicine and technology were Clay’s fields of interest right from his childhood. He said that he had always wished to have the power and ability to change the fate of people who were headed for death and make them live instead. His decision to take the genetics route, however, was primarily motivated by his experience with a relative who had been diagnosed with cancer. Clay explained that the nature of treatment that his relative was being subjected to fell below his expectations- it was brutal according to him. From that point, he started familiarizing with various cancer treatment procedures including chemotherapy that his relative went through, amputation, and radical surgery. With that background knowledge, he decided to pursue genetics.
Now in his 9th year at Seattle Genetics, Dr. Siegall admits that he made a good choice in venturing into entrepreneurship. He said that besides his devotion to revolutionizing cancer treatment, his other motive behind establishing Seattle Genetics was to make a fortune out of it. He told Inspirery that he makes good money through getting drugs approved by the FDA, as well as through having his technologies licensed. Production partnerships between Seattle and other companies also earn the company some handsome revenue, something that makes entrepreneurship a good venture for Dr. Clay. The good revenues, however, started flowing in after about three years in business. Siegall admits that he was contemplating quitting the whole thing altogether due to the low revenues the company was generating especially in 1999 and 2000.
About Clay Siegall
Dr. Siegall puts to good use the Ph.D. in genetics that he acquired from George Washington University to help cancer patients live longer. He does this with an added advantage of having a B.S in Zoology.
To this end, Clay Siegall has had a hand in the development of 20 FDA-approved drugs or more. He has also led Seattle Genetics in sealing partnership deals with reputable firms such as Genentech and Pfizer.